Trial Profile
Vorinostat (Zolinza) in Combination With (Velcade) Versus Vorinostat Alone in Refractory or Recurrent Advanced CTCL: A Randomized Phase III Study.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Vorinostat (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Biomarker; Therapeutic Use
- 05 Jul 2011 New trial record